Evidence map›Paper›PMID 42076760›Full record

ArticleVeterinary sciences2026

Topical Application of Preserved and Unpreserved Bevacizumab Eye Drops Improves Ocular Surface Parameters in Dogs with Chronic Keratitis: A Pilot Study.

Ulrike Lessiak, Stefan Kummer, Michael Schueller-Wambacher, Alexander Tichy, Barbara Nell

Abstract read
In one paragraph

Article in Veterinary sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ulrike LessiakDepartment of Companion Animals and Horses, University of Veterinary Medicine, 1210 Vienna, Austria.
Stefan KummerVetCore Facility for Research, University of Veterinary Medicine, 1210 Vienna, Austria.ORCID 0000-0002-0746-1403
Michael Schueller-WambacherHospital Pharmacy, University of Veterinary Medicine, 1210 Vienna, Austria.ORCID 0000-0002-8668-0400
Alexander TichyDepartment of Biomcal Sciences, University of Veterinary Medicine, 1210 Vienna, Austria.ORCID 0000-0001-8668-3858
Barbara NellDepartment of Companion Animals and Horses, University of Veterinary Medicine, 1210 Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Corneal neovascularization (CNV) in dogs causes chronic ocular surface inflammation, which may disrupt tear film stability and meibomian gland function. As bevacizumab inhibits abnormal vessel growth and affects tear composition, it may benefit dogs with ocular surface disorders. The aim of this pilot study was to evaluate the effects of bevacizumab eye drops on the ocular surface in dogs with chronic CNV. Fourteen eyes from nine client-owned dogs were included. Dogs received either preserved (B

Indexed as

anti-VEGFinterferometrymeibographyocular surfaceOSA-Vettear meniscus height

Identifiers

PMID42076760
PMCPMC13120455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.